(Q44400981)

2 December 2017

title

Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study (English)

1 reference

2 December 2017

1 reference

Enrique Baca

1

1 reference

2 December 2017

Manuel González de Chávez

2

1 reference

2 December 2017

Mauro García-Toro

3

1 reference

2 December 2017

Francisco Pérez-Arnau

4

1 reference

2 December 2017

Alberto Porras-Chavarino

5

1 reference

2 December 2017

language of work or name

1 reference

1 May 2003

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

2 December 2017

published in

1 reference

2 December 2017

volume

27

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

493-500

1 reference

Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Comparative efficacy of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

From the Bench to the Trench: A Comparison of Sertraline Treatment of Major Depression in Clinical and Research Patient Samples

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Mental disorders and disability among patients in a primary care group practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Sertraline in the treatment of panic disorder: a double-blind multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900038-1

7 January 2021

10.1016/S0278-5846(03)00038-1

Identifiers

DOI

1 reference

2 December 2017

1 reference